Answers are grounded in this paper and cite their sources.
Co-culture reveals reciprocal signaling between endothelial cells and tubular epithelial cells, implying a role in renal fibrosis.
Background Renal fibrosis is a common pathological feature of chronic kidney disease (CKD), but its underlying mechanisms remain incompletely understood. Our previous study demonstrated that insulin-like growth factor-binding protein 5 (IGFBP-5) promotes glycolytic reprogramming in vascular endothelial cells (ECs) and exacerbates renal inflammation in diabetic kidney disease (DKD). Methods Human renal proximal tubular epithelial cells (HK-2) and human umbilical vein endothelial cells (HUVECs) were used. A co-culture system was employed to investigate endothelial cell–tubular epithelial cell (EC-TEC) crosstalk. Unilateral ureteral obstruction (UUO) and aristolochic acid nephropathy (ANN) models were established in wild-type (WT), global IGFBP-5−/−, and endothelial-specific Tie-2 Cre; IGFBP-5−/− mice. Expression levels of IGFBP-5, TGF-β1, and fibrosis markers were assessed to to investigate the role of IGFBP-5 in renal fibrogenesis. Results Serum IGFBP-5 levels were significantly elevated in patients with chronic kidney disease (CKD). Genetic ablation of IGFBP-5 attenuated renal fibrosis in murine models, demonstrating its critical role in fibrogenesis. IGFBP-5 was predominantly expressed in endothelial cells (ECs), and endothelial-specific deletion delayed renal fibrosis progression via suppression of the TGF-β1/Smad3 pathway. In vitro, endothelial-derived IGFBP-5 promoted a profibrotic phenotypic transformation in TECs through AKT-mediated phosphorylation of the TGF-β1/Smad3 axis. Conversely, TGF-β1 stimulated IGFBP-5 biosynthesis and secretion in ECs via the ERK signaling pathway, establishing a self-amplifying feedback loop. This reciprocal IGFBP-5/TGF-β1 crosstalk between ECs and TECs was confirmed in co-culture experiments. Conclusion Our findings reveal a novel endothelial cell–tubular epithelial cell (EC-TEC) crosstalk axis mediated by reciprocal IGFBP-5/TGF-β1 signaling, which is a critical driver of renal fibrosis. IGFBP-5 emerges as a promising therapeutic target for inhibiting renal fibrogenesis in CKD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: